NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01556776,A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy,https://clinicaltrials.gov/study/NCT01556776,,COMPLETED,"CLLM1 is a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that compares the efficacy and safety of oral lenalidomide maintenance therapy to that of placebo maintenance therapy in high-risk subjects with Chronic Lymphocytic Leukemia (CLL) who have achieved at least a partial response (PR) and either:

* MRD levels of ≥ 10-2 or
* MRD levels of ≥ 10-4 - \< 10-2 combined with at least one of the following factors:

  * an unmutated IGHV-status
  * 17p-deletion or
  * TP53 mutation after first line therapy with FCR, FR, BR or FC (in case of of contraindications to receive Rituximab).",NO,Chronic Lymphocytic Leukemia,DRUG: lenalidomide|DRUG: Placebo,"Progression-free survival (PFS) based on independent review committee, Time from the date of randomization to the date of first documented disease progression (as defined by the iWCLL response criteria, see section 4.11.1.2) or death by any cause, whichever occurs first., up to 6 years","Progression-free survival (PFS) based on investigator's assessment, Time from the date of randomization to the date of first documented disease progression (as defined by the iWCLL response criteria, see section 4.11.1.2) or death by any cause, whichever occurs first., up to 6 years|Overall survival (OS), Time from the date of randomization to the date of death due to any cause, up to 6 years|Safety - adverse events (AEs), Type, frequency and severity of adverse events (AEs) and relationship of AEs to lenalidomide or placebo; premature withdrawals, up to 6 years|Miminimal residual disease (MRD) levels in peripheral blood (PB), MRD levels assessed by quantitative highly sensitive flow cytometry (MRD flow) of the PB, up to 6 years",,German CLL Study Group,Celgene,ALL,"ADULT, OLDER_ADULT",PHASE3,89,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CLLM1|2011-004698-98|RV-CLL-GCLLSG-0725,2012-07-20,2016-03,2021-01-14,2012-03-16,,2022-01-05,"University Hospital Cologne, Cologne, 50924, Germany|German CLL Study Group, Cologne, 50937, Germany",
